|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shin JY, Yoon JK and Marwaha G: Progress
in the treatment and outcomes for Early-Stage non-small cell lung
cancer. Lung. 196:351–358. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lagos GG, Izar B and Rizvi NA: Beyond
tumor PD-L1: Emerging genomic biomarkers for checkpoint inhibitor
immunotherapy. Am Soc Clin Oncol Educ Book. 40:1–11.
2020.PubMed/NCBI
|
|
5
|
Travis WD: Lung cancer pathology: Current
concepts. Clin Chest Med. 41:67–85. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vansteenkiste J, Crino L, Dooms C,
Douillard JY, Faivre-Finn C, Lim E, Rocco G, Senan S, Van Schil P,
Veronesi G, et al: 2nd ESMO Consensus Conference on lung cancer:
Early-stage non-small-cell lung cancer consensus on diagnosis,
treatment and follow-up. Ann Oncol. 25:1462–1474. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pirker R: Adjuvant chemotherapy in
patients with completely resected non-small cell lung cancer.
Transl Lung Cancer Res. 3:305–310. 2014.PubMed/NCBI
|
|
8
|
Torre LA, Siegel RL and Jemal A: Lung
cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brambilla E and Gazdar A: Pathogenesis of
lung cancer signalling pathways: Roadmap for therapies. Eur Respir
J. 33:1485–1497. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kadara H, Scheet P, Wistuba II and Spira
AE: Early events in the molecular pathogenesis of lung cancer.
Cancer Prev Res (Phila). 9:518–527. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peng WX, Koirala P and Mo YY:
LncRNA-mediated regulation of cell signaling in cancer. Oncogene.
36:5661–5667. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long noncoding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huarte M: The emerging role of lncRNAs in
cancer. Nat Med. 21:1253–1261. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cheetham SW, Gruhl F, Mattick JS and
Dinger ME: Long noncoding RNAs and the genetics of cancer. Br J
Cancer. 108:2419–2425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma HP, Wang LX, Li W, Guo HH, Wu Y and Li
XY: Upregulation of LINC00504 is associated with aggressive
progression and poor prognosis in non-small cell lung cancer. Eur
Rev Med Pharmacol Sci. 24:699–703. 2020.PubMed/NCBI
|
|
16
|
Qiu C, Li S, Sun D and Yang S: lncRNA PVT1
accelerates progression of non-small cell lung cancer via targeting
miRNA-526b/EZH2 regulatory loop. Oncol Lett. 19:1267–1272.
2020.PubMed/NCBI
|
|
17
|
Wang Z, Zhang J, Yang B, Li R, Jin L, Wang
Z, Yu H, Liu C, Mao Y and You Q: Long Intergenic noncoding RNA
00261 acts as a tumor suppressor in non-small cell lung cancer via
regulating miR-105/FHL1 Axis. J Cancer. 10:6414–6421. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shangguan WJ, Liu HT, Que ZJ, Qian FF, Liu
LS and Tian JH: TOB1-AS1 suppresses non-small cell lung cancer cell
migration and invasion through a ceRNA network. Exp Ther Med.
18:4249–4258. 2019.PubMed/NCBI
|
|
19
|
Gao YP, Li Y, Li HJ and Zhao B: LncRNA
NBR2 inhibits EMT progression by regulating Notch1 pathway in
NSCLC. Eur Rev Med Pharmacol Sci. 23:7950–7958. 2019.PubMed/NCBI
|
|
20
|
Wang Y, Luo X, Liu Y, Han G and Sun D:
Long noncoding RNA RMRP promotes proliferation and invasion via
targeting miR-1-3p in non-small-cell lung cancer. J Cell Biochem.
120:15170–15181. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bian C, Yuan L and Gai H: A long
non-coding RNA LINC01288 facilitates non-small cell lung cancer
progression through stabilizing IL-6 mRNA. Biochem Biophys Res
Commun. 514:443–449. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cesana M, Cacchiarelli D, Legnini I,
Santini T, Sthandier O, Chinappi M, Tramontano A and Bozzoni I: A
long noncoding RNA controls muscle differentiation by functioning
as a competing endogenous RNA. Cell. 147:358–369. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fan J, Zhang J, Huang S and Li P: lncRNA
OSER1-AS1 acts as a ceRNA to promote tumorigenesis in
hepatocellular carcinoma by regulating miR-372-3p/Rab23 axis.
Biochem Biophys Res Commun. 521:196–203. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sibio S, Sica GS, Di Carlo S, Cardi M, Di
Giorgio A, Sollazzo BM and Sammartino P: Surgical treatment of
intraperitoneal metastases from lung cancer: Two case reports and a
review of the literature. J Med Case Rep. 13:2622019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yi E, Kim D, Cho S, Kim K and Jheon S:
Clinical outcomes of cytoreductive surgery combined with
intrapleural perfusion of hyperthermic chemotherapy in advanced
lung adenocarcinoma with pleural dissemination. J Thorac Dis.
8:1550–1560. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42((Database Issue)): D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang L, Cho KB, Li Y, Tao G, Xie Z and Guo
B: Long Noncoding RNA (lncRNA)-mediated competing endogenous RNA
networks provide novel potential biomarkers and therapeutic targets
for colorectal cancer. Int J Mol Sci. 20:57582019. View Article : Google Scholar
|
|
30
|
Li J, Chen M and Yu B: miR-433 suppresses
tumor progression via Smad2 in non-small cell lung cancer. Pathol
Res Pract. 215:1525912019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tang L, Wang T, Zhang Y, Zhang J, Zhao H,
Wang H, Wu Y and Liu K: Long non-coding RNA AWPPH promotes
postoperative distant recurrence in resected non-small cell lung
cancer by upregulating transforming growth factor beta 1 (TGF-β1).
Med Sci Monit. 25:2535–2541. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bai Y, Zhang G, Chu H, Li P and Li J: The
positive feedback loop of lncRNA DANCR/miR-138/Sox4 facilitates
malignancy in non-small cell lung cancer. Am J Cancer Res.
9:270–284. 2019.PubMed/NCBI
|
|
33
|
Liu X, Lu X, Zhen F, Jin S, Yu T, Zhu Q,
Wang W, Xu K, Yao J and Guo R: LINC00665 induces acquired
resistance to Gefitinib through recruiting EZH2 and activating
PI3K/AKT pathway in NSCLC. Mol Ther Nucleic Acids. 16:155–161.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang Y, Li Y, Han L, Zhang P and Sun S:
SUMO1P3 is associated clinical progression and facilitates cell
migration and invasion through regulating miR-136 in non-small cell
lung cancer. Biomed Pharmacother. 113:1086862019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang B, Wang H, Wang Q, Xu J, Jiang P and
Li W: Knockout of lncRNA UCA1 inhibits drug resistance to gefitinib
via targeting STAT3 signaling in NSCLC. Minerva Med. 110:273–275.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li B, Gu W and Zhu X: NEAT1 mediates
paclitaxel-resistance of non-small cell of lung cancer through
activation of Akt/mTOR signalling pathway. J Drug Target.
27:1061–1067. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hutchinson JN, Ensminger AW, Clemson CM,
Lynch CR, Lawrence JB and Chess A: A screen for nuclear transcripts
identifies two linked noncoding RNAs associated with SC35 splicing
domains. BMC Genomics. 8:392007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang JJ, Huang YQ, Song W, Li YF, Wang H,
Wang WJ and Huang M: Comprehensive analysis of the lncRN-associated
competing endogenous RNA network in breast cancer. Oncol Rep.
42:2572–2582. 2019.PubMed/NCBI
|
|
39
|
Xu F, Zhao Y, Qin G, Huan Y, Li L and Gao
W: Comprehensive analysis of competing endogenous RNA networks
associated with cholangiocarcinoma. Exp Ther Med. 18:4103–4112.
2019.PubMed/NCBI
|
|
40
|
Wang Q, Liu S, Zhao X, Wang Y, Tian D and
Jiang W: MiR-372-3p promotes cell growth and metastasis by
targeting FGF9 in lung squamous cell carcinoma. Cancer Med.
6:1323–1330. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kamato D and Little PJ: Smad2 linker
region phosphorylation is an autonomous cell signalling pathway:
Implications for multiple disease pathologies. Biomed Pharmacother.
124:1098542020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen T, Zhu J, Cai T, Du W, Zhang Y, Zhu
Q, Liu Z and Huang JA: Suppression of non-small cell lung cancer
migration and invasion by hsa-miR-486-5p via the TGF-β/SMAD2
signaling pathway. J Cancer. 10:6014–6024. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Othman N and Nagoor NH: Overexpression of
miR3615p plays an oncogenic role in human lung adenocarcinoma
through the regulation of SMAD2. Int J Oncol. 54:306–314.
2019.PubMed/NCBI
|
|
44
|
Wang Z, Lu Y, Sheng B, Ding Y and Cheng X:
Catalpol inhibits TGF-β1-induced epithelial-mesenchymal transition
in human non-small-cell lung cancer cells through the inactivation
of Smad2/3 and NF-κB signaling pathways. J Cell Biochem. Sep
11–2018.doi: 10.1002/jcb.27535 (Epub Ahead of Print).
|
